1596 lines
111 KiB
Text
1596 lines
111 KiB
Text
|
||
<!DOCTYPE html>
|
||
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
|
||
<head>
|
||
<!-- Google Tag Manager -->
|
||
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
||
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
||
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
||
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
||
})(window,document,'script','dataLayer','GTM-5B8TQK');</script>
|
||
<!-- End Google Tag Manager -->
|
||
<meta charset="utf-8" />
|
||
<style>body #backtotop {background: #20558A;border-color: #20558A;color: #ffffff;}body #backtotop:hover { background: #153759; border-color: #153759; }</style>
|
||
<meta name="description" content="“Kratom” commonly refers to an herbal substance that can produce opioid- and stimulant-like effects. Kratom and kratom-based products are currently legal and accessible in many areas." />
|
||
<meta name="abstract" content="“Kratom” commonly refers to an herbal substance that can produce opioid- and stimulant-like effects. Kratom and kratom-based products are currently legal and accessible in many areas." />
|
||
<link rel="canonical" href="https://nida.nih.gov/research-topics/kratom" />
|
||
<link rel="image_src" href="https://nida.nih.gov/sites/default/files/images/pain-addiction_JSJ_8JJ2467_optimized.jpg" />
|
||
<meta name="rights" content="Unless otherwise specified, NIDA publications and videos are available for your use and may be reproduced in their entirety without permission from NIDA. Citation of the source is appreciated, using the following language: Source: National Institute on Dr" />
|
||
<meta property="og:site_name" content="National Institute on Drug Abuse" />
|
||
<meta property="og:type" content="article" />
|
||
<meta property="og:url" content="https://nida.nih.gov/research-topics/kratom" />
|
||
<meta property="og:title" content="Kratom | National Institute on Drug Abuse" />
|
||
<meta property="og:description" content="“Kratom” commonly refers to an herbal substance that can produce opioid- and stimulant-like effects. Kratom and kratom-based products are currently legal and accessible in many areas." />
|
||
<meta property="og:image:url" content="https://nida.nih.gov/sites/default/files/images/pain-addiction_JSJ_8JJ2467_optimized.jpg" />
|
||
<meta property="og:updated_time" content="2024-09-27" />
|
||
<meta property="og:see_also" content="https://nida.nih.gov/frequently-asked-questions" />
|
||
<meta property="og:locale" content="en_US" />
|
||
<meta property="article:author" content="National Institute on Drug Abuse" />
|
||
<meta property="article:publisher" content="National Institute on Drug Abuse" />
|
||
<meta property="article:tag" content="2022" />
|
||
<meta property="article:published_time" content="2022-03-25" />
|
||
<meta property="article:modified_time" content="2024-09-27" />
|
||
<meta name="twitter:card" content="summary_large_image" />
|
||
<meta name="twitter:description" content="“Kratom” commonly refers to an herbal substance that can produce opioid- and stimulant-like effects. Kratom and kratom-based products are currently legal and accessible in many areas." />
|
||
<meta name="twitter:site" content="@NIDAnews" />
|
||
<meta name="twitter:title" content="Kratom | National Institute on Drug Abuse" />
|
||
<meta name="twitter:site:id" content="102234123" />
|
||
<meta name="twitter:creator" content="@NIDAnews" />
|
||
<meta name="twitter:creator:id" content="102234123" />
|
||
<meta name="twitter:image" content="https://nida.nih.gov/sites/default/files/images/pain-addiction_JSJ_8JJ2467_optimized.jpg" />
|
||
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
|
||
<meta name="MobileOptimized" content="width" />
|
||
<meta name="HandheldFriendly" content="true" />
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
|
||
<link rel="icon" href="/themes/custom/solstice/favicon.ico" type="image/vnd.microsoft.icon" />
|
||
<link rel="alternate" hreflang="es" href="https://nida.nih.gov/es/areas-de-investigacion/el-kratom" />
|
||
<link rel="alternate" hreflang="en" href="https://nida.nih.gov/research-topics/kratom" />
|
||
<script>window.a2a_config=window.a2a_config||{};a2a_config.callbacks=[];a2a_config.overlays=[];a2a_config.templates={};a2a_config.icon_color = "#6e6e6e";</script>
|
||
<style>.a2a_svg {border-radius:0 !important;margin-right:.5rem;}
|
||
.addtoany_list a:hover span {opacity:1 !important;}
|
||
.a2a_button_email .a2a_svg:hover {background: #7B0A07 !important;}
|
||
.a2a_button_facebook .a2a_svg:hover {background: #3b5998 !important;}
|
||
.a2a_button_twitter .a2a_svg:hover {background: #1da1f3 !important;}</style>
|
||
|
||
<title>Kratom | National Institute on Drug Abuse (NIDA)</title>
|
||
<link rel="stylesheet" media="all" href="/sites/default/files/css/css_54Q_e1wo1pYHBAMDXKgGlC8JTnWAIi01ONTIBPGPf8U.css?delta=0&language=en&theme=solstice&include=eJx1j-FuwzAIhF-Ixo9kEZukKMR4BlfN28_tsq3TNokfxyd03GHOrliOgKeYlqbFYca0RdcxNbzo6HR3SOOCikdMSVtmLeEXAeO9CkXr7UZH-LGBHea0D18joLfORe9hFZ1RLuaHcFnBVMw50b98GR8NRpqBt5BbryjTuULaKLNre0n4pT4KUsmQ2NGf6U9xmUXTBhUbrg3r1T59v8nUS-2zsF1pGKhom0f4TAt2cdjHWwwLi1ObEtaHKWDeucRHAbKoN2qNM4U_aRSe3wGJHJ9o" />
|
||
<link rel="stylesheet" media="all" href="/sites/default/files/css/css_0UGPPljqXAoDwdSUvZq0UvQ80T8PQF3R2-oEN0XWALc.css?delta=1&language=en&theme=solstice&include=eJx1j-FuwzAIhF-Ixo9kEZukKMR4BlfN28_tsq3TNokfxyd03GHOrliOgKeYlqbFYca0RdcxNbzo6HR3SOOCikdMSVtmLeEXAeO9CkXr7UZH-LGBHea0D18joLfORe9hFZ1RLuaHcFnBVMw50b98GR8NRpqBt5BbryjTuULaKLNre0n4pT4KUsmQ2NGf6U9xmUXTBhUbrg3r1T59v8nUS-2zsF1pGKhom0f4TAt2cdjHWwwLi1ObEtaHKWDeucRHAbKoN2qNM4U_aRSe3wGJHJ9o" />
|
||
<link rel="stylesheet" media="print" href="/sites/default/files/css/css_DdDSCruNdF_ZfkPZJO53VAt8xts9SZrIVSlXqjoL6m8.css?delta=2&language=en&theme=solstice&include=eJx1j-FuwzAIhF-Ixo9kEZukKMR4BlfN28_tsq3TNokfxyd03GHOrliOgKeYlqbFYca0RdcxNbzo6HR3SOOCikdMSVtmLeEXAeO9CkXr7UZH-LGBHea0D18joLfORe9hFZ1RLuaHcFnBVMw50b98GR8NRpqBt5BbryjTuULaKLNre0n4pT4KUsmQ2NGf6U9xmUXTBhUbrg3r1T59v8nUS-2zsF1pGKhom0f4TAt2cdjHWwwLi1ObEtaHKWDeucRHAbKoN2qNM4U_aRSe3wGJHJ9o" />
|
||
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Open+Sans:300,400,600,700|Roboto+Slab:100,300,400,700&display=swap" />
|
||
|
||
|
||
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
|
||
<link rel="apple-touch-icon" href="/themes/custom/solstice/images/apple-touch-icon.png">
|
||
</head>
|
||
<body class="path-node body">
|
||
<!-- Google Tag Manager (noscript) -->
|
||
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5B8TQK"
|
||
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
|
||
<!-- End Google Tag Manager (noscript) -->
|
||
<a href="#main-content" class="visually-hidden focusable">
|
||
Skip to main content
|
||
</a>
|
||
|
||
<div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
|
||
|
||
<div class="l-page-container">
|
||
<div class="mobile-overlay" id="overlay" aria-hidden="true"></div>
|
||
<section class="usa-banner clearfix" >
|
||
<div id="block-solstice-uswdsbanner">
|
||
|
||
|
||
<div class="usa-accordion">
|
||
<header class="usa-banner__header">
|
||
<div class="usa-banner__inner">
|
||
<div class="grid-col-auto">
|
||
<img alt="USA flag icon" aria-hidden="true" class="usa-banner__header-flag" src="/themes/custom/solstice/images/uswds/us_flag_small.png" />
|
||
</div>
|
||
<div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
|
||
<p class="usa-banner__header-text">
|
||
An official website of the United States government
|
||
</p>
|
||
<p class="usa-banner__header-action">Here’s how you know</p>
|
||
</div>
|
||
<button type="button" class="usa-accordion__button usa-banner__button" aria-expanded="false" aria-controls="gov-banner-default-default">
|
||
<span class="usa-banner__button-text">Here’s how you know</span>
|
||
</button>
|
||
</div>
|
||
</header>
|
||
<div class="usa-banner__content usa-accordion__content" id="gov-banner-default-default" hidden>
|
||
<div class="grid-row grid-gap-lg">
|
||
<div class="usa-banner__guidance tablet:grid-col-6">
|
||
<img class="usa-banner__icon usa-media-block__img" src="/themes/custom/solstice/images/uswds/icon-dot-gov.svg" role="img" alt="government icon" aria-hidden="true"/>
|
||
<div class="usa-media-block__body">
|
||
<p>
|
||
<strong>Official websites use .gov</strong><br />A
|
||
<strong>.gov</strong> website belongs to an official government
|
||
organization in the United States.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
<div class="usa-banner__guidance tablet:grid-col-6">
|
||
<img class="usa-banner__icon usa-media-block__img" src="/themes/custom/solstice/images/uswds/icon-https.svg" role="img" alt="lock icon" aria-hidden="true"/>
|
||
<div class="usa-media-block__body">
|
||
<p>
|
||
<strong>Secure .gov websites use HTTPS</strong><br />A
|
||
<strong>lock</strong> (
|
||
<span class="icon-lock">
|
||
<svg
|
||
xmlns="http://www.w3.org/2000/svg"
|
||
width="52"
|
||
height="64"
|
||
viewBox="0 0 52 64"
|
||
class="usa-banner__lock-image"
|
||
role="img"
|
||
aria-labelledby="banner-lock-description-default"
|
||
focusable="false"
|
||
>
|
||
<title id="banner-lock-title-default">Lock</title>
|
||
<desc id="banner-lock-description-default">Locked padlock icon</desc>
|
||
<path
|
||
fill="#000000"
|
||
fill-rule="evenodd"
|
||
d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z"
|
||
/>
|
||
</svg> </span>) or <strong>https://</strong> means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
</section>
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<header role="banner" class="header">
|
||
|
||
|
||
<div class="row v-align-middle space-between width-100">
|
||
<div class="header-inner col-12 col-desktop-8">
|
||
<div id="block-solstice-branding" class="site-branding col-10">
|
||
<div class="logo">
|
||
<a href="/" title="NIDA Home" rel="home">
|
||
<img src="/themes/custom/solstice/nida_logo_color-cropped-cropped.svg" alt="NIDA Home" width="282" height="37" />
|
||
</a>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<button role="button" aria-label="Menu" aria-haspopup="menu" aria-expanded="false" class="button button-primary button--menu hide-desktop ml-1" id="menu-btn">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="white-icon svg-inline">
|
||
<path d="M16 132h416c8.837 0 16-7.163 16-16V76c0-8.837-7.163-16-16-16H16C7.163 60 0 67.163 0 76v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16z"/>
|
||
</svg>
|
||
</button>
|
||
</div>
|
||
<div class="col-12 col-desktop-4 align-end">
|
||
<div class="top-bar-switcher">
|
||
<div id="block-solstice-globallanguage">
|
||
|
||
|
||
<div><a class="" href="/es" lang="es">en español</a></div>
|
||
</div>
|
||
|
||
</div>
|
||
<div id="block-sitesearchheader">
|
||
|
||
|
||
|
||
<div> <form method="get" action="/search" class="form-horizontal form-small">
|
||
<label for="search" class="is-vishidden">Search Component</label>
|
||
<input type="search" name="query" id="search" placeholder="Search" required oninvalid="this.setCustomValidity('Please enter at least one keyword.')" oninput="setCustomValidity('')">
|
||
<input type="hidden" name="sort" id="sort" value="_score">
|
||
<button class="button button-primary button--small"><i title="Search" class="fas fa-search"></i></button>
|
||
</form><!-- end search-form -->
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
|
||
</header>
|
||
|
||
<nav role="navigation" aria-labelledby="block-megamenu-menu" id="block-megamenu" class="primary-nav">
|
||
|
||
<div class="visually-hidden" id="block-megamenu-menu">Mega Menu</div>
|
||
|
||
|
||
|
||
|
||
<ul data-region="primary_menu" class="primary-nav--list row menu menu-level-0">
|
||
<li class="menu-item col primary-nav--list-item menu-item-1">
|
||
<a href="/" class="menu-item menu-item-1 primary-nav--link" data-drupal-link-system-path="<front>">Home</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown secondary-nav">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded menu-item--active-trail col primary-nav--list-item menu-item-2">
|
||
<a href="/research-topics" class="menu-item menu-item--expanded menu-item--active-trail menu-item-2 primary-nav--link" data-drupal-link-system-path="node/1861">Research Topics</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/research-topics">Research Topics</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/addiction-science" data-drupal-link-system-path="node/341">Addiction Science</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/cannabis">Cannabis (Marijuana)</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/emerging-drug-trends" data-drupal-link-system-path="node/52514">Emerging Drug Trends</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/fentanyl" data-drupal-link-system-path="node/50578">Fentanyl</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/harm-reduction" data-drupal-link-system-path="node/50074">Harm Reduction</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/heroin" data-drupal-link-system-path="node/331">Heroin</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/hiv" data-drupal-link-system-path="node/49621">HIV</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item menu-item--active-trail secondary-nav--list-item">
|
||
<a href="/research-topics/kratom" data-drupal-link-system-path="node/48990" class="is-active" aria-current="page">Kratom</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/methamphetamine" data-drupal-link-system-path="node/53515">Methamphetamine</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/opioids" data-drupal-link-system-path="node/52427">Opioids</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/prevention" data-drupal-link-system-path="node/51497">Prevention</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/psychedelic-dissociative-drugs" data-drupal-link-system-path="node/50846">Psychedelic and Dissociative Drugs</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/psilocybin-magic-mushrooms" title="Psilocybin (Magic Mushrooms)" data-drupal-link-system-path="node/51885">Psilocybin (Magic Mushrooms)</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/syringe-services-programs" data-drupal-link-system-path="node/48992">Syringe Services Programs</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/stigma-discrimination" data-drupal-link-system-path="node/48993">Stigma and Discrimination</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/tobacconicotine-vaping" data-drupal-link-system-path="node/337">Tobacco/Nicotine and Vaping</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research-topics/treatment" data-drupal-link-system-path="node/49630">Treatment</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
<div class="more-button-container">
|
||
|
||
<div><a href="/research-topics">More Research Topics</a></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div>
|
||
|
||
<ul>
|
||
<li><a href="/research-topics/parents-educators">Resources for Parents and Educators</a></li>
|
||
<li><a href="/research-topics/addiction-science/words-matter-preferred-language-talking-about-addiction">Words Matter: Preferred Language</a></li>
|
||
<li><a href="/research-topics/commonly-used-drugs-charts">Commonly Used Drugs Chart</a></li>
|
||
<li><a href="/research-topics/publications">NIDA Publications</a></li>
|
||
<li><a href="/research-topics/trends-statistics/infographics">Infographics</a></li>
|
||
<li><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9bf223ac-30d7-4c3e-af0a-1c0176830b48" href="/multimedia">Multimedia</a></li>
|
||
</ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded col primary-nav--list-item menu-item-3">
|
||
<a href="/research" class="menu-item menu-item--expanded menu-item-3 primary-nav--link" data-drupal-link-system-path="node/22803">Research & Training</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/research">Research & Training</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/nida-research-programs-activities" data-drupal-link-system-path="node/22824">NIDA Research Programs & Activities</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/clinical-research" data-drupal-link-system-path="node/22807">Clinical Research</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/nih-policies-guidance" data-drupal-link-system-path="node/22810">NIH Policies & Guidance</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/research-data-measures-resources" data-drupal-link-system-path="node/22825">Research Data, Measures, & Resources</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/research-training-career-development" data-drupal-link-system-path="node/22808">Research Training & Career Development</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/resources-grants-contracts" data-drupal-link-system-path="node/22809">Resources for Grants & Contracts</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div>
|
||
|
||
<ul>
|
||
<li><a href="/drug-topics/opioids/nidas-role-in-nih-heal-initiative">HEAL Initiative</a></li>
|
||
<li><a href="/research/research-data-measures-resources/nida-drug-supply-program">NIDA Drug Supply Program</a></li>
|
||
<li><a href="/research/nih-policies-guidance/clinical-trials-stewardship">Clinical Trials Stewardship</a></li>
|
||
<li><a href="/research/research-training-career-development/training-career-development-fellowships-grants">Fellowships & Grants</a></li>
|
||
<li><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="09aee0c9-6892-4300-ae47-2065268bbb6c" href="/international">International Program</a></li>
|
||
</ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded col primary-nav--list-item menu-item-4">
|
||
<a href="/nidamed-medical-health-professionals" class="menu-item menu-item--expanded menu-item-4 primary-nav--link" data-drupal-link-system-path="node/22863">Clinical Resources</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/nidamed-medical-health-professionals">NIDAMED: Clinical Resources</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/resources-for-your-professional-discipline-specialty" data-drupal-link-system-path="node/22769">For Your Discipline</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/health-professions-education" data-drupal-link-system-path="node/22723">Health Professions Education</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/vaping-marijuana-other-drugs" data-drupal-link-system-path="node/22726">Marijuana and Other Drugs</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/opioids-pain-management" data-drupal-link-system-path="node/22725">Opioid Crisis and Pain Management</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/screening-tools-prevention" data-drupal-link-system-path="node/22727">Screening Tools & Prevention</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/nidamed-medical-health-professionals/treatment-resources" data-drupal-link-system-path="node/22768">Treatment</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div><ul><li><a href="/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools" data-entity-type="node" data-entity-uuid="0a7e9511-2db1-4cf1-bb9d-bc35684904d6" data-entity-substitution="canonical">Screening and Assessment Tools Chart</a></li><li><a href="/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction" data-entity-type="node" data-entity-uuid="550685bd-7757-4249-8f65-def5bd1b7027" data-entity-substitution="canonical">Words Matter - Terms to Use and Avoid When Talking About Addiction</a></li></ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded col primary-nav--list-item menu-item-5">
|
||
<a href="/funding" class="menu-item menu-item--expanded menu-item-5 primary-nav--link" data-drupal-link-system-path="node/22854">Grants & Funding</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/funding">Grants & Funding</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/funding/nida-funding-opportunities" data-drupal-link-system-path="node/22851">NIDA Funding Opportunities</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/funding/small-business-innovation-research-sbir-technology-transfer-sttr-programs" title="Small Business Innovation Research (SBIR) and Technology Transfer (STTR) Programs" data-drupal-link-system-path="node/47954">Small Business Innovation Research (SBIR) and Technology Transfer (STTR) Programs</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/funding/trans-nih-funding-opportunities" data-drupal-link-system-path="node/22852">Trans-NIH Funding Opportunities</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/funding/nida-office-acquisitions-contracting" title="NIDA Office of Acquisitions Contracting" data-drupal-link-system-path="node/1443">NIDA Office of Acquisitions Contracting</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/research/research-data-measures-resources/technology-transfer" title="Technology Transfer" data-drupal-link-system-path="node/1451">Technology Transfer</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div>
|
||
|
||
<ul>
|
||
<li><a href="/research/resources-grants-contracts/peer-review">Peer Review</a></li>
|
||
<li><a href="/research/resources-grants-contracts/grant-contract-application-process/forms">Grant Application Forms</a></li>
|
||
<li><a href="/research/resources-grants-contracts/grant-contract-application-process">Grants & Contract Application Process</a></li>
|
||
<li><a href="/funding-app?sort=rel_date:desc&document_types=NOSI&issuing_institution=NIDA%20Primary">NIDA Notice of Special Interest (NOSI)</a></li>
|
||
</ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded col primary-nav--list-item menu-item-6">
|
||
<a href="/news-events" class="menu-item menu-item--expanded menu-item-6 primary-nav--link" data-drupal-link-system-path="node/1860">News & Events</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/news-events">News</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/news-events/news-releases" data-drupal-link-system-path="news-events/news-releases">News Releases</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/noras-blog" data-drupal-link-system-path="node/36652">Nora's Blog</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/news-events/meetings-events" title="Meeting and Events" data-drupal-link-system-path="node/37562">Meetings & Events</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/news-events/nida-in-news" data-drupal-link-system-path="node/47623">NIDA in the News</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/news-events/nida-asks" data-drupal-link-system-path="node/51529">NIDA Asks</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div>
|
||
|
||
<ul>
|
||
<li><a href="/news-events/contact-press-office">Contact the Press Office</a><br>
|
||
<a href="mailto:media@nida.nih.gov" title="mailto:media@nida.nih.gov">media@nida.nih.gov</a><br>
|
||
<span>301-443-6245</span></li>
|
||
</ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
<li class="menu-item menu-item--expanded col primary-nav--list-item menu-item-7">
|
||
<a href="/about-nida" class="menu-item menu-item--expanded menu-item-7 primary-nav--link" data-drupal-link-system-path="node/2389">About NIDA</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown menu-dropdown-0 menu-type-default secondary-nav">
|
||
|
||
<div class="nav-section header-content">
|
||
|
||
<div class="section-header">
|
||
|
||
<div><a href="/about-nida">About NIDA</a></div>
|
||
|
||
</div>
|
||
<ul class="secondary-nav--list menu menu-level-1">
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/advisory-boards-groups" data-drupal-link-system-path="node/3422">Advisory Boards and Review Groups</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/directors-page" data-drupal-link-system-path="node/2340">Director's Page</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/legislative-activities" data-drupal-link-system-path="node/2390">Legislative Activities</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/organization" data-drupal-link-system-path="node/3228">Organization</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
|
||
<li class="menu-item secondary-nav--list-item">
|
||
<a href="/about-nida/working-nida" data-drupal-link-system-path="node/36660">Working at NIDA</a>
|
||
|
||
|
||
<div class="menu_link_content menu-link-contentmega-menu view-mode-default menu-dropdown">
|
||
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</div>
|
||
<div class="nav-section">
|
||
|
||
<div class="nav-list-block">
|
||
|
||
<div>
|
||
<div><div class="h2 font-primary text-med-2 mt-0-5">Quick Links</div><ul><li><a href="/about-nida/legislative-activities/budget-information">FY Budget Information</a></li><li><a href="/about-nida/organization/cctn/clinical-trials-network-ctn">Clinical Trials Network</a></li><li><a href="/about-nida/frequently-asked-questions">Frequently Asked Questions</a></li><li><a href="/about-nida/contact-us">Contact Us</a></li></ul></div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</nav>
|
||
|
||
|
||
|
||
<div class="breadcrumb">
|
||
<div>
|
||
<div id="block-solstice-breadcrumbs">
|
||
|
||
|
||
<nav role="navigation" aria-labelledby="system-breadcrumb">
|
||
<div id="system-breadcrumb" class="visually-hidden">Breadcrumb</div>
|
||
<ol class="breadcrumb-list no-bullets">
|
||
<li class="breadcrumb-list-item">
|
||
<a href="/">Home</a>
|
||
</li>
|
||
<li class="breadcrumb-list-item">
|
||
<a href="/research-topics">Research Topics</a>
|
||
</li>
|
||
<li class="breadcrumb-list-item">
|
||
Kratom
|
||
</li>
|
||
</ol>
|
||
</nav>
|
||
|
||
</div>
|
||
<div data-drupal-messages-fallback class="hidden"></div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div class="content">
|
||
<div class="content-inner">
|
||
|
||
|
||
<main role="main" class="main inner">
|
||
<a id="main-content" tabindex="-1"></a>
|
||
<div class="above-content relative">
|
||
<div>
|
||
<div id="block-nidapagetitle">
|
||
|
||
|
||
<h1 class="h1 l-inner-b">
|
||
|
||
<span>Kratom</span>
|
||
|
||
</h1>
|
||
</div>
|
||
|
||
|
||
|
||
<div class="language-switcher-language-url formats-list-block title-area font-secondary" id="block-languageswitcher-2" role="navigation">
|
||
|
||
|
||
<ul class="links formats-list no-bullets"><li hreflang="es" data-drupal-link-system-path="node/48990" class="formats-list-item language"> <span lang="es"><a href="/es/areas-de-investigacion/el-kratom" class="language-link" hreflang="es" data-drupal-link-system-path="node/48990">En español</a></span>
|
||
</li></ul>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div class="main-wrapper">
|
||
|
||
<div class="layout-center-content ">
|
||
|
||
<div>
|
||
<div class="content-river">
|
||
<div id="block-nida-vic-adaptive-system-main">
|
||
|
||
|
||
|
||
<article data-history-node-id="48990">
|
||
<div>
|
||
<div class="topic-intro-wrapper topic-intro-wrapper--research-topic full-width-wrapper l-section--accent-rt pb-1-2 mb-2-4">
|
||
<div class="topic-intro full-width-contents l-inner-sides row-no-wrap-d">
|
||
|
||
<div class="col-desktop-8 col-12">
|
||
<div class="l-card height-100 rt-highlights--wrapper">
|
||
|
||
|
||
|
||
<div><h2>Highlights</h2><div class="align-right image-medium">
|
||
|
||
<div class="media-image">
|
||
|
||
<div>
|
||
<div class="visually-hidden">Image</div>
|
||
<div> <img loading="lazy" src="/sites/default/files/styles/content_image_medium/public/images/pain-addiction_JSJ_8JJ2467_optimized.jpg?itok=SAKmDcPt" width="426" height="284" alt="Close-up of researchers inspecting cultivated kratom leaves.">
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<span class="image-credit">
|
||
|
||
<div>©University of Florida College of Pharmacy</div>
|
||
|
||
</span>
|
||
</div>
|
||
</div>
|
||
<ul><li>“Kratom” commonly refers to an herbal substance that can produce <a href="#affect-body">opioid- and stimulant-like effects</a>. Kratom and kratom-based products are currently legal and accessible in many areas, though U.S. and international agencies continue to review emerging evidence to inform <a href="#legal">kratom policy</a>.<sup>1</sup></li><li>While there are no uses for kratom approved by the U.S. Food and Drug Administration, people <a href="#why-use-kratom">report using kratom</a> to manage drug withdrawal symptoms and cravings (especially related to opioid use), pain, fatigue and mental health problems.<sup>2,3,4</sup> NIDA supports and conducts research to evaluate <a href="#medicine">potential medicinal uses</a> for kratom and related chemical compounds.</li><li>NIDA also supports research towards better understanding the health and safety effects of kratom use. Rare but serious effects have been reported in people who use kratom, including psychiatric, cardiovascular, gastrointestinal and respiratory problems.<sup>1,5</sup> Compared to deaths from other drugs, a very small <a href="#safe">number of deaths</a> have been linked to kratom products and nearly all cases involved other drugs or contaminants.<sup>1,6,7,8,9,10</sup></li></ul></div>
|
||
|
||
|
||
|
||
|
||
</div> </div>
|
||
</div> </div>
|
||
<div class="content-inner research-topic-inner">
|
||
<aside class="layout-sidebar-left" role="complementary">
|
||
<h2 class="research-topic-inner--title"><a href="/research-topics">Research Topics</a></h2>
|
||
<div class="research-topic-inner--content">
|
||
<div>
|
||
<div class="visually-hidden">Related Topic Pages</div>
|
||
<div>
|
||
<div><span>Kratom</span></div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</aside>
|
||
|
||
<article class="main">
|
||
|
||
|
||
<div>
|
||
<div> <div class="paragraph paragraph--type--accordion paragraph--view-mode--default iq-accordion mb-2-4">
|
||
<button class="button button-primary button--small expand" aria-label="Expand All">Expand All</button>
|
||
|
||
<div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="kratom" class="iq-accordion--heading" aria-expanded="false"><h2>What is kratom?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>“Kratom” refers to both <em>Mitragyna speciosa,</em> a tree native to Southeast Asia, and to products derived from its leaves that are marketed as herbal supplements. Kratom leaves contain many chemical compounds (known as bioactive alkaloids) that can affect the body. The most well-studied compounds related to kratom are mitragynine and 7-hydroxymitragynine.<sup>1 </sup>(See <a href="#kratom-compounds">How do kratom compounds work in the brain?</a>)</p><p>Much is still unknown about chemical compounds related to kratom, the short- and long-term health and safety impacts of kratom use and kratom’s potential therapeutic uses. NIDA supports and conducts research on kratom and related chemical compounds to help inform kratom policy and health decision-making around kratom use. (See <a href="#advancing-research">How is NIDA advancing research on about kratom?</a>)</p><p>While kratom or its related compounds have not been approved by the U.S. Food and Drug Administration as safe and effective for any medical use, people report using kratom products to alleviate drug withdrawal symptoms and cravings (particularly for opioids), to alleviate pain and to help manage mental health problems.<sup>3,4,11,12,13,14,15,16</sup> (See <a href="#why-use-kratom">Why do people use kratom?</a>) NIDA is particularly interested in studying how kratom use may impact opioid use, which continues to drive the <a href="/drug-topics/opioids/opioid-overdose-crisis">drug overdose epidemic</a> in the United States.</p><p>People typically use kratom by swallowing raw plant matter in capsule or powder form, mixing kratom powder into food or drinks, brewing the leaves as a tea, or taking liquid kratom extract.<a href="#references"><sup>1</sup></a><sup> </sup>People who use kratom report both stimulant-like effects (increased energy, alertness and rapid heart rate) and effects that are similar to opioids and sedatives (relaxation, pain relief and confusion).<sup>10,17</sup> Studies and case reports have also indicated rare adverse effects may be associated with kratom or individual kratom compounds.<sup>1,9</sup> (See <a href="#affect-body">How does kratom affect the body?</a>; <a href="#safe">Is kratom safe?</a>)</p><p>Anthropologists report that kratom has been used in Southeast Asia for hundreds of years as a multi-purpose remedy in traditional medicine, to increase alertness and energy while working and during social gatherings.<sup>18</sup> While estimates of the scope of kratom use in the United States vary,<sup>19</sup> the expansion of kratom vendors and increasing case reports suggest kratom use has become more common over the past two decades.<sup>20</sup></p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="affect-body" class="iq-accordion--heading" aria-expanded="false"><h2>How does kratom affect the body?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>Researchers are still learning how kratom and kratom compounds affect the body, as well as how short- and long-term kratom use may impact health. While evidence is quickly evolving, early studies have revealed important information about how the drug works.</p><ul><li><strong>Effects may vary widely.</strong> Like all drugs, kratom’s effects may depend on the amount taken, potency (concentration and strength), formulation of the product, the way it is ingested, other drugs in a person’s system, a person’s underlying medical conditions, and a person’s previous experience with the substance, among other factors.<sup>3,</sup> <sup>4, 17 </sup>Importantly, kratom products vary, so effects are difficult to predict. Some kratom products have been found to contain contaminants that produce effects not associated with kratom or kratom compounds alone.<sup>6, 7, 21</sup> Learn more: <a href="#safe">Is kratom safe?</a></li><li><strong>Kratom produces opioid- and stimulant-like effects.</strong> People who use kratom report both stimulant-like effects (increased energy, alertness and rapid heart rate) and effects that are similar to opioids and sedatives (relaxation, pain relief and confusion). While many people who use kratom report that smaller doses of kratom produce stimulant-like effects and larger doses produce opioid- or sedative-like effects,<sup>4</sup> studies have not yet established that these effects depend on the amount or method of kratom consumed.<sup>10, 17</sup></li><li><strong>Mitragynine, 7-hydroxymitragynine, and other kratom compounds drive these effects.</strong> The effect of kratom products can vary depending on the concentration and combination of specific kratom compounds within the product. While kratom leaves contain many chemical compounds that may influence the human body, the most well-studied is mitragynine. When ingested, mitragynine breaks down into another chemical called 7-hydroxymitragynine, which also influences the body and is an important subject of research.<sup>22</sup> Learn more: <a href="#kratom_compounds">How do kratom compounds work in the brain?</a></li><li><strong>Adverse effects range from mild to severe.</strong> Some people who use kratom have reported mild side effects, such as nausea, constipation, dizziness and drowsiness.<sup>3, 4</sup> In case reports, clinicians report seeing patients with a wide range of rare but serious adverse effects associated with kratom exposure—including mental and neurological symptoms (confusion, tremors and seizures), heart and lung problems (high blood pressure and slow breathing), gastrointestinal problems (nausea and vomiting) and liver problems.<sup>1, 23 </sup>A very small number of deaths have been linked to kratom products, and nearly all cases involved other drugs or contaminants.<sup>1,6, 7, 8, 21, 24</sup> (See <a href="#safe">Is kratom safe?</a>)</li><li><strong>Drug interactions may influence effects.</strong> Studies suggest many people who use kratom also use other drugs and have conditions for which medications are often prescribed.<sup>3,</sup> <sup>4, 17 </sup>Case reports suggest using kratom in combination with other drugs (sometimes called polysubstance use) may produce severe adverse effects, such as liver problems or even death.<sup>25</sup> More research is needed to better understand the impact of using kratom in combination with other substances. (See <a href="#safe">Is kratom safe?</a>)</li><li><strong>Long-term health effects are not well understood.</strong> Because kratom research is relatively new compared to more widely used drugs, there is little evidence to determine how kratom use may affect someone over time. Case reports do show regular, long-term, kratom use in large amounts may be associated with serious liver problems. These cases appear to occur unpredictably in a small minority of people who use kratom, and it is unclear what role other substances and underlying health conditions may play.<sup>9, 26</sup> (See <a href="#safe">Is kratom safe?</a>) Researchers are also still learning how often and to what extent people who use kratom experience withdrawal or substance use disorder symptoms related to kratom use. Learn more: <a href="#addictive-withdrawal">Is kratom addictive? Do people experience kratom withdrawal?</a></li><li><strong>Research on potential therapeutic effects of kratom is ongoing.</strong> Researchers have not proven kratom to be safe or effective for any medical purpose, though kratom has been used in traditional medicine.<sup>18</sup> Many people who use kratom products report doing so to self-treat pain, anxiety, depression, fatigue, and drug cravings and withdrawal symptoms (especially related to opioid use).<sup>1, 3</sup> NIDA supports and conducts research on therapeutic uses of kratom and related compounds. Learn more: <a href="#medicine">Could kratom be used as medicine?</a></li></ul></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="kratom-compounds" class="iq-accordion--heading" aria-expanded="false"><h2>How do kratom compounds work in the brain?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><figure role="group" class="align-right colorbox-medium">
|
||
<div class="colorbox-medium">
|
||
|
||
<div class="media-image">
|
||
|
||
<div>
|
||
<div class="visually-hidden">Image</div>
|
||
<div>
|
||
<a href="https://nida.nih.gov/sites/default/files/images/nida_k_1_optimized.jpg" aria-label="{"alt":"2D chemical structures of kratom compounds mitragynine (top) and 7-hydroxymitragynine (bottom)"}" role="button" title data-colorbox-gallery="gallery-all-1-vYf0tqMUY" class="colorbox" aria-controls="colorbox-P2YIY3KmopY" data-cbox-img-attrs="{"alt":"2D chemical structures of kratom compounds mitragynine (top) and 7-hydroxymitragynine (bottom)"}"><img id="colorbox-P2YIY3KmopY" src="/sites/default/files/styles/content_image_medium/public/images/nida_k_1_optimized.jpg?itok=yBDQvNmq" width="426" height="284" alt="2D chemical structures of kratom compounds mitragynine (top) and 7-hydroxymitragynine (bottom)" loading="lazy">
|
||
|
||
</a>
|
||
</div>
|
||
</div>
|
||
|
||
<span class="image-credit">
|
||
|
||
<div>Credit: NIDA</div>
|
||
|
||
</span>
|
||
</div>
|
||
</div>
|
||
|
||
<figcaption>2D chemical structures of kratom compounds mitragynine (top) and 7-hydroxymitragynine (bottom). </figcaption>
|
||
</figure>
|
||
<p>Kratom leaves contain many chemical compounds (known as bioactive alkaloids) that influence the body. The most well-studied kratom-related compounds are mitragynine and 7-hydroxymitragynine. Mitragynine is found in kratom leaves and breaks down into 7-hydroxymitragynine in the body when digested.<sup>22, 27</sup> Both activate mu-opioid receptors (specific molecular structures on the surface of nerve cells), but the resulting effects only partially compare to those of <a href="/drug-topics/opioids">opioids</a> like <a href="/drug-topics/heroin">heroin</a> or oxycodone.<sup>28</sup></p><p>Some research suggests that mitragynine and 7-hydroxymitragynine may not cause some of the more serious adverse effects associated with opioid use—such as respiratory depression (trouble breathing)—that can occur during a life-threatening opioid overdose.<sup>29</sup> Scientists also have observed that mitragynine may bind to adrenergic receptors, serotonin receptors and dopamine receptors, which may be responsible for some of the arousing effects some people who use kratom report experiencing.<sup>1, 30, 31</sup></p><p>Better understanding where and how kratom compounds work in the brain is an active area of NIDA-funded research. This basic research plays an important role in identifying kratom’s health effects and potential therapeutic uses. Learn more: <a href="#advancing-research">How is NIDA advancing research on kratom?</a></p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="advancing-research" class="iq-accordion--heading" aria-expanded="false"><h2>How is NIDA advancing research on kratom?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>Scientific research on kratom is relatively new compared to research on more widely used drugs. Much is still unknown about chemical compounds related to kratom, the short- and long-term health and safety impacts of kratom use and kratom’s potential therapeutic uses. In response to reports of increases in kratom exposures in the United States<sup>6</sup> and emerging questions about kratom and its health effects, NIDA is supporting research on kratom’s use, effects, mechanisms and therapeutic potential.</p><p>To help inform kratom policy and health decision-making around kratom use, NIDA conducts and supports research on how kratom compounds work in the brain, as well as research on kratom use patterns, health effects, therapeutic uses and drug interactions. Because many people who use kratom also report using or previously using <a href="/drug-topics/opioids/opioid-overdose-crisis">opioids</a> and experiencing opioid use disorder,<sup> 2, 3</sup> NIDA is particularly interested in studying how kratom use may impact opioid use, which has driven the <a href="/drug-topics/opioids/opioid-overdose-crisis">drug overdose epidemic</a> in the United States. Early studies have found that some people report using kratom to ease craving and withdrawal symptoms associated with other substances, including opioids and stimulants.<sup>5, 11, 13, 14, 15, 16</sup></p><p>NIDA and the <a href="https://heal.nih.gov/" rel="noopener noreferrer" target="_blank">NIH HEAL (Helping to End Addiction Long-term<sup>®</sup>) Initiative</a> are supporting several studies evaluating kratom and related compounds as potential treatments for chronic pain and for opioid withdrawal and opioid use disorder. <a href="https://reporter.nih.gov/search/KHEbKQnH7EypHqk7dDsGvA/project-details/10259369" rel="noopener noreferrer" target="_blank">One of these projects</a> (also supported by the National Center for Advancing Translational Sciences and National Institute of Neurological Disorders and Stroke) includes efforts to help develop new medications, including kratom-derived products, as potential treatments for opioid use disorder.</p><p>NIDA also supports preclinical research to better understand how multiple kratom compounds produce complex pharmacological and behavioral effects, to evaluate kratom as a potential therapy for opioid use disorder and to investigate the chemistry and biology of kratom-derived compounds for their use as therapeutic drugs and as research tools. (See <a href="#medicine">Could kratom be used as medicine?</a>)</p><p>See more <a href="https://reporter.nih.gov/search/-pm6ufRB0kqVRo9p8eJTrw/projects" rel="noopener noreferrer" target="_blank">NIDA-funded projects related to kratom</a>, and learn more about <a href="https://www.clinicaltrials.gov/ct2/results?cond=&term=kratom%2C+mitragynine&cntry=&state=&city=&dist=" rel="noopener noreferrer" target="_blank">clinical trials involving kratom</a>.</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="scope" class="iq-accordion--heading" aria-expanded="false"><h2>What is the scope of kratom use in the United States?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>Among people aged 12 or older in 2021, an estimated 0.6% (or about 1.7 million people) reported using kratom in the past 12 months (2021 DT 8.22).*<br><span class="text-embed-small">Source: </span><a href="https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report" data-mce-href="https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report"><span class="text-embed-small">2021 National Survey on Drug Use and Health</span></a><span class="text-embed-small">**</span></p><p>* Estimates of how many people regularly use kratom vary.<sup>19</sup><br>** The COVID-19 pandemic had an impact on data collection for the 2021 National Survey on Drug Use and Health (NSDUH). For more information, please see the <a href="https://www.samhsa.gov/data/release/2021-national-survey-drug-use-and-health-nsduh-releases">2021 NSDUH Frequently Asked Questions</a> from the Substance Abuse and Mental Health Services Administration.</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="why-use-kratom" class="iq-accordion--heading" aria-expanded="false"><h2>Why do people use kratom?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>NIDA conducts and supports research to better understand the diverse reasons people use kratom.<sup>3</sup> Kratom has been used in its native Southeast Asia for centuries to produce opioid- and stimulant-like effects, including increased energy and relaxation.<sup>18</sup> (See <a href="#affect_body">How does kratom affect the body?</a>)</p><p>In recent years, studies suggest people across the globe use kratom for these and many other reasons.<sup>1, 3, 4 </sup>Researchers have found that people report using kratom to alleviate pain, to address symptoms of mental health conditions like anxiety and depression, to help stop or reduce opioid or other substance use and to manage withdrawal symptoms and cravings related to opioids and other drugs. Most report multiple reasons for using kratom.<sup>3, 11, 32</sup></p><p>While research is underway to explore possible therapeutic benefits (see <a href="#medicine">Could kratom be used as medicine?)</a>, kratom products have not been demonstrated to be safe and effective for any medical condition. Of note, <a href="/drug-topics/trends-statistics/infographics/medications-opioid-overdose-withdrawal-addiction">safe and effective medications</a> are approved to help control withdrawal symptoms and cravings associated with opioid use disorder, as well as other substance use disorders. Learn more about <a href="https://www.painconsortium.nih.gov/" rel="noopener noreferrer" target="_blank">pain treatment from the NIH Pain Consortium</a> and about <a href="https://www.nimh.nih.gov/" rel="noopener noreferrer" target="_blank">mental health treatment from the National Institute of Mental Health</a>.</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="safe" class="iq-accordion--heading" aria-expanded="false"><h2>Is kratom safe?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>U.S. and international agencies have expressed concern that kratom products may cause serious harm.<sup>1</sup> There are no uses for kratom approved by the U.S. Food and Drug Administration (FDA), and the FDA has <a href="https://www.fda.gov/news-events/public-health-focus/fda-and-kratom" rel="noopener noreferrer" target="_blank">warned consumers not to use kratom products</a> because of potential adverse effects.</p><p>The FDA, the <a href="https://www.cdc.gov/" rel="noopener noreferrer" target="_blank">U.S. Centers for Disease Control and Prevention</a> and NIDA support and conduct research to measure and better understand the short- and long-term safety risks of kratom use and inform policy around kratom regulation.</p><p>Currently, several safety issues related to kratom have been identified:</p><ul><li><strong>Kratom products may contain harmful contaminants. </strong>There are no uses for kratom approved by the FDA, and kratom products have been found to contain contaminants that produce effects not associated with kratom or kratom compounds alone, including heavy metals and harmful bacteria.<sup>1, 6, 7, 8, 21 </sup>Of note, researchers and regulators have found similar instances of contamination in many other products marketed as herbal supplements.<sup>33, 34</sup> Read more about <a href="https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements">supplement regulation from the FDA</a>.<br> </li><li><strong>Adverse effects range from mild to severe.</strong> Some people who use kratom have reported mild side effects, such as nausea, constipation, dizziness and drowsiness.<sup>3, 4</sup> In case reports, clinicians report seeing patients with a wide range of very rare but serious adverse effects associated with kratom exposure—including mental and neurological symptoms (confusion, tremors and seizures), heart and lung problems (high blood pressure and slow breathing), gastrointestinal problems (nausea and vomiting) and liver problems.<sup>1, 23 </sup>Researchers continue to study potential adverse effects in humans, animal models and cells, including possible damage to the cardiovascular system.<sup>10, 23, 35 </sup>(See <a href="#affect-body">How does kratom affect the body?</a>)<br> </li><li><strong>A very small number of deaths have been linked to kratom products compared to deaths from other drugs.</strong><sup>1, 6, 7, 8, 24 </sup>While more research is needed, it appears that fatal overdose from kratom use alone is extremely rare. A 2019 report found that 11 deaths between 2011 and 2017 in the United States were associated with kratom exposure, including two deaths associated with kratom exposure alone.<sup>6 </sup>In contrast, during that same period, more than 200,000 people died from <a href="/drug-topics/trends-statistics/overdose-death-rates">opioid-related overdose</a>.<sup>36</sup><br> </li><li><strong>Drug interactions may influence effects. </strong>Studies suggest many people who use kratom also use other drugs and have conditions for which medications are often prescribed,<sup>3,</sup> <sup>4, 17 </sup>and case reports suggest polysubstance use (the use of multiple drugs) involving kratom has been associated with severe adverse effects, such as death and liver problems.<sup>25</sup> More research is needed in this area to assess the safety of using kratom in combination with other substances.<br> </li><li><strong>Long-term health and safety effects are not well understood.</strong> Because kratom research is relatively new compared to research on more widely used drugs, there is little evidence to determine how kratom use may affect someone over time. Case reports do show regular, long-term, kratom use in large amounts may be associated with serious liver problems. These cases appear to occur unpredictably in a small minority of people who use kratom, and it is unclear what role other substances and underlying health conditions may play.<sup>9, 26</sup><br> </li><li><strong>Effects on pregnancy are not well understood. </strong>Very little research is available on kratom use before, during and after pregnancy, but there have been reports of opioid-like <a href="https://medlineplus.gov/ency/article/007313.htm" rel="noopener noreferrer" target="_blank">neonatal abstinence syndrome</a> in infants born to women who regularly use kratom.<sup>37</sup> Learn more: <a href="#pregnancy">How does kratom use affect pregnancy?</a><br> </li><li><strong>Safety effects of intoxication are not well understood.</strong> The impact of kratom intoxication (taking enough to be impaired) on driving, operating heavy machinery, or performing other tasks that could be dangerous if impaired has not been extensively studied.<sup>9, 38, 39</sup></li></ul><p>Learn more about <a href="https://www.fda.gov/news-events/public-health-focus/fda-and-kratom" rel="noopener noreferrer" target="_blank">kratom and safety from the FDA</a>.</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="pregnancy" class="iq-accordion--heading" aria-expanded="false"><h2>How does kratom use affect pregnancy?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>Very little research is available on kratom use before, during and after pregnancy. A 2021 report suggests that many cases of kratom use during pregnancy likely also involve the use of other substances, and the effects of kratom alone on pregnancy are difficult to determine without further research. The same report identified at least five cases of opioid-like <a href="https://medlineplus.gov/ency/article/007313.htm" rel="noopener noreferrer" target="_blank">neonatal abstinence syndrome</a> in infants born to women who regularly used kratom but not opioids. The infants in these cases all responded well to standard treatments given to infants experiencing neonatal abstinence syndrome related to opioids.<sup>37</sup></p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="addictive-withdrawal" class="iq-accordion--heading" aria-expanded="false"><h2>Is kratom addictive? Do people experience kratom withdrawal?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>NIDA conducts and supports research to better understand how often and to what extent people who use kratom experience withdrawal and substance use disorder symptoms related to kratom use.</p><p>To be diagnosed with a substance use disorder, a person must meet specific diagnostic criteria for continued, compulsive substance use despite negative consequences. The <em>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</em> (DSM-5)—a reference text published by the American Psychiatric Association that health professionals use to diagnose substance use disorders and other psychiatric disorders—does not include a specific diagnosis related to kratom use.<sup>40</sup> However, some researchers studying kratom have modified criteria to study kratom use patterns and symptoms that resemble other substance use disorders.<sup>3</sup></p><p>Studies suggest people may experience mild to moderate withdrawal symptoms when they stop regular kratom use,<sup>41, 42</sup> but more research is needed to understand to what extent people develop substance use disorder symptoms related to kratom.<sup>1, 3, 9</sup></p><p>Preliminary data from anonymous surveys of people who use kratom suggest a minority of people report experiencing kratom-related withdrawal symptoms and a smaller minority report experiencing substance use disorder symptoms related to kratom use.<sup>3</sup></p><p>Some experts are concerned about kratom’s addictive potential because the main kratom compounds, mitragynine and 7-hydroxymitragynine, partially activate the same receptors (specific molecular structures on the surface of nerve cells) in the brain on which drugs with known addictive properties act. However, researchers have observed that the way kratom compounds activate these receptors may reduce the potential for addiction relative to <a href="/drug-topics/opioids">opioids</a>.<sup>28, 29, 30, 31</sup> Further, studies in animal models indicate that the addictive potential of mitragynine and 7-hydroxymitragynine may differ from one another.<sup>43</sup> Further research is needed to better understand how various compounds related to kratom interact to influence the risk of withdrawal and addiction. (See <a href="#kratom-compounds">How do kratom compounds work in the brain?</a>)</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="symptoms-treated" class="iq-accordion--heading" aria-expanded="false"><h2>How are withdrawal and substance use disorder symptoms related to kratom use treated?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>While withdrawal and substance use disorder symptoms related to kratom use have not been extensively studied, some people who use kratom report experiencing them.<sup>1, 3, 9</sup> (See <a href="#addictive-withdrawal">Is kratom addictive? Do people experience kratom withdrawal?</a>) There are currently no approved medical therapies for these conditions. In very limited cases, some researchers have reported using medications<sup>44, 45, 46</sup> and other therapies<sup>47</sup> to address withdrawal and substance use disorder symptoms related to kratom use<sup>41 </sup>in humans and animal models—though robust clinical trials are still needed to evaluate these and other experimental treatment options.</p><p><a href="/about-nida/contact-us#help">See more information on seeking substance use treatment and other medical attention.</a></p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="medicine" class="iq-accordion--heading" aria-expanded="false"><h2>Could kratom be used as medicine?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>NIDA and other institutes at NIH support and conduct research to evaluate potential medicinal uses for kratom and kratom compounds. While kratom has not been proven safe or effective for any medical purpose, kratom has been used in traditional medicine in some countries,<sup>1, 18</sup> and many people who use kratom report doing so to self-medicate for pain, anxiety, depression, substance use disorders and substance withdrawal.<sup>1, 3, 11</sup> Studies in animal models suggest kratom and related compounds potentially have other therapeutic properties, such as antidepressant and pain-relieving properties, that may warrant further study.<sup>1, 48</sup></p><p>Of particular interest to NIDA, early studies suggest kratom and kratom compounds warrant further study as experimental treatments for substance use disorders, specifically opioid use disorder.<sup>9, 48</sup> Such treatments are urgently needed to help curb the <a href="/drug-topics/opioids/opioid-overdose-crisis">drug overdose epidemic</a> in the United States. NIDA and its partners conduct and support research evaluating kratom and related compounds as potential treatments for chronic pain and for opioid withdrawal and opioid use disorder. Learn more: <a href="#advancing_research">How is NIDA advancing research on kratom?</a></p></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--accordion-row iq-accordion--row paragraph--view-mode--default clear-both mt-0-0">
|
||
|
||
<button id="legal" class="iq-accordion--heading" aria-expanded="false"><h2>Is kratom legal?</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true"><p>While kratom use or sale has been banned or restricted in several countries,<sup>9 </sup>kratom products are currently legal and accessible online<sup>49</sup> and in stores in many areas of the United States. The U.S. Drug Enforcement Administration (DEA) has listed kratom as a “drug of concern,” though kratom and kratom compounds are not listed on the <a href="https://www.dea.gov/drug-information/drug-scheduling" rel="noopener noreferrer" target="_blank">U.S. schedule of controlled substances</a>.</p><p>In 2021, the <a href="https://www.who.int/groups/ecdd" rel="noopener noreferrer" target="_blank">World Health Organization’s (WHO) Expert Committee on Drug Dependence</a> (ECDD) examined the evidence on kratom’s health effects and concluded that there is insufficient evidence of adverse effects that would warrant additional critical review or inclusion in the United Nations list of internationally <a href="https://www.who.int/our-work/access-to-medicines-and-health-products/controlled-substances" rel="noopener noreferrer" target="_blank">controlled substances</a>. (See the <a href="https://www.who.int/publications/m/item/kratom-mitragynine-7-hydroxymitragynine-critical-review-report" rel="noopener noreferrer" target="_blank">full WHO ECDD report on kratom</a>.) Kratom remains on the list of substances under surveillance by the WHO ECDD.</p><p>Learn more about kratom and its legal status in the United States from the <a href="https://www.dea.gov/factsheets/kratom/" rel="noopener noreferrer" target="_blank">Drug Enforcement Administration (DEA)</a>.</p></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<div>
|
||
|
||
|
||
|
||
<div class="paragraph paragraph--type--summary-cards-row-of-2 paragraph--view-mode--default l-section">
|
||
<div class="l-inner-b card-grid">
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div class="mb-3-6"></div>
|
||
|
||
<div>
|
||
<div>
|
||
|
||
<div class="paragraph paragraph--type--full-width-text paragraph--view-mode--default l-inner-b">
|
||
|
||
<h2 class="h2 pb-1-2">
|
||
Find More Resources on Kratom
|
||
</h2>
|
||
|
||
<div><ul><li>Learn more about kratom regulation and safety from the <a href="https://www.fda.gov/news-events/public-health-focus/fda-and-kratom">U.S. Food and Drug Administration (FDA)</a>.</li><li>Learn more about kratom and its legal status from the <a href="https://www.dea.gov/factsheets/kratom">Drug Enforcement Administration (DEA)</a>.</li><li>Learn more about kratom products marketed as herbal supplements from the <a href="https://www.nccih.nih.gov/health/kratom">National Institutes of Health (NIH) National Center for Complementary and Integrative Health (NCCIH)</a>.</li></ul></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
<div class="iq-accordion iq-accordion--references clear-both mb-2-4 pt-0-6">
|
||
<button id="references" class="iq-accordion--heading" aria-expanded="false"><h2>References</h2><span class="iq-accordion--toggle closed h3"></span></button>
|
||
<div class="iq-accordion--content" aria-hidden="true">
|
||
<div><ol><li class="long-url-wrap" id="footnote-1">United Nations, Commission on Narcotic Drugs. <a href="https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_64Reconvened/ECN72021_CRP12_V2108992.pdf">Summary of assessments, findings and recommendations of the 44th World Health Organization’s (WHO) Expert Committee on Drug Dependence (ECDD), 11–15 October 2021.</a> Vienna; 9-10 December 2021. Report No. E/CN.7/2021/CRP.12 <a href="#reference-1">[1]</a></li><li class="long-url-wrap" id="footnote-2">Palamar JJ. <a href="https://doi.org/10.1016/j.amepre.2021.02.004">Past-year kratom use in the U.S.: Estimates from a nationally representative sample. </a><em>Am J Prev Med</em>. 2021;61(2):240-245. doi:10.1016/j.amepre.2021.02.004 <a href="#reference-2">[2]</a></li><li class="long-url-wrap" id="footnote-3">Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. <a href="https://doi.org/10.1016/j.drugalcdep.2020.107849">Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.</a> <em>Drug Alcohol Depend</em>. 2020;208:107849. doi:10.1016/j.drugalcdep.2020.107849 <a href="#reference-3">[3]</a></li><li class="long-url-wrap" id="footnote-4">Grundmann O. <a href="https://doi.org/10.1016/j.drugalcdep.2017.03.007">Patterns of Kratom use and health impact in the US-Results from an online survey.</a> <em>Drug Alcohol Depend</em>. 2017;176:63-70. doi:10.1016/j.drugalcdep.2017.03.007 <a href="#reference-4">[4]</a></li><li class="long-url-wrap" id="footnote-5">Leong Bin Abdullah MFI, Singh D. <a href="https://doi.org/10.3389/fphar.2021.726003">The adverse cardiovascular effects and cardiotoxicity of kratom (<em>Mitragyna speciosa</em> korth.): A comprehensive review.</a> <em>Front Pharmacol</em>. 2021;12:726003. Published 2021 Sep 27. doi:10.3389/fphar.2021.726003 <a href="#reference-5">[5]</a></li><li class="long-url-wrap" id="footnote-6">Post S, Spiller HA, Chounthirath T, Smith GA. <a href="https://doi.org/10.1080/15563650.2019.1569236">Kratom exposures reported to United States poison control centers: 2011-2017.</a> <em>Clin Toxicol (Phila)</em>. 2019;57(10):847-854. doi:10.1080/15563650.2019.1569236 <a href="#reference-6">[6]</a></li><li class="long-url-wrap" id="footnote-7">Kronstrand R, Roman M, Thelander G, Eriksson A. <a href="https://doi.org/10.1093/anatox/35.4.242">Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton.</a> <em>J Anal Toxicol</em>. 2011;35(4):242-247. doi:10.1093/anatox/35.4.242 <a href="#reference-7">[7]</a></li><li class="long-url-wrap" id="footnote-8">Henningfield JE, Grundmann O, Babin JK, Fant RV, Wang DW, Cone EJ. <a href="https://doi.org/10.1016/j.ypmed.2019.105851">Risk of death associated with kratom use compared to opioids.</a> <em>Prev Med</em>. 2019;128:105851. doi:10.1016/j.ypmed.2019.105851 <a href="#reference-8">[8]</a></li><li class="long-url-wrap" id="footnote-9">United Nations, Expert Committee on Drug Dependence. <a href="https://www.who.int/publications/m/item/kratom-mitragynine-7-hydroxymitragynine-critical-review-report">Pre-review report: Kratom (<em>Mytragyna speciosa</em>), mitragynine, and 7-hydroxymitragynine.</a> 11–15 October 2021. Geneva. <a href="#reference-9">[9]</a></li><li class="long-url-wrap" id="footnote-10">Leong Bin Abdullah MFI, Singh D, Swogger MT, Rahim AA, Vicknasingam B. <a href="https://doi.org/10.1016/j.ajp.2019.07.008">The prevalence of psychotic symptoms in kratom (<em>Mitragyna speciosa </em>korth) users in Malaysia<em>.</em></a> <em>Asian J Psychiatr</em>. 2019;43:197-201. doi:10.1016/j.ajp.2019.07.008 <a href="#reference-10">[10]</a></li><li class="long-url-wrap" id="footnote-11">Smith KE, Rogers JM, Schriefer D, Grundmann O. <a href="https://doi.org/10.1016/j.drugalcdep.2021.108879">Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.</a> <em>Drug Alcohol Depend</em>. 2021;226:108879. doi:10.1016/j.drugalcdep.2021.108879 <a href="#reference-11">[11]</a></li><li class="long-url-wrap" id="footnote-12">Singh D, Narayanan S, Vicknasingam B, et al. <a href="https://doi.org/10.1097/adm.0000000000000876">The use of kratom (<em>Mitragyna speciosa</em> korth) among people who co-use heroin and methamphetamine in Malaysia.</a> <em>J Addict Med</em>. 2021;10.1097/ADM.0000000000000876. doi:10.1097/ADM.0000000000000876 <a href="#reference-12">[12]</a></li><li class="long-url-wrap" id="footnote-13">Vicknasingam B, Narayanan S, Beng GT, Mansor SM. <a href="https://doi.org/10.1016/j.drugpo.2009.12.003">The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy.</a> <em>Int J Drug Policy</em>. 2010;21(4):283-288. doi:10.1016/j.drugpo.2009.12.003 <a href="#reference-13">[13]</a></li><li class="long-url-wrap" id="footnote-14">Saref A, Suraya S, Singh D, et al. <a href="https://doi.org/10.1080/02791072.2019.1686553">Self-Report Data on regular consumption of illicit drugs and HIV risk behaviors after kratom (<em>Mitragyna Speciosa</em> korth) initiation among illicit drug users in Malaysia.</a><em> J Psychoactive Drugs</em>. 2020;52(2):138-144. doi:10.1080/02791072.2019.1686553 <a href="#reference-14">[14]</a></li><li class="long-url-wrap" id="footnote-15">Smith KE, Lawson T. <a href="https://doi.org/10.1016/j.drugalcdep.2017.08.034">Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.</a> <em>Drug Alcohol Depend</em>. 2017;180:340-348. doi:10.1016/j.drugalcdep.2017.08.034 <a href="#reference-15">[15]</a></li><li class="long-url-wrap" id="footnote-16">Boyer EW, Babu KM, Macalino GE. <a href="https://doi.org/10.1080/10550490701525368">Self-treatment of opioid withdrawal with a dietary supplement, kratom.</a> <em>Am J Addict</em>. 2007;16(5):352-356. doi:10.1080/10550490701525368 <a href="#reference-16">[16]</a></li><li class="long-url-wrap" id="footnote-17">Singh D, Narayanan S, Grundmann O, Dzulkapli EB, Vicknasingam B. <a href="https://doi.org/10.1080/10826084.2019.1645178">Effects of Kratom (<em>Mitragyna Speciosa</em> korth) use in regular users.</a> <em>Subst Use Misuse</em>. 2019;54(14):2284-2289. doi:10.1080/10826084.2019.1645178 <a href="#reference-17">[17]</a></li><li class="long-url-wrap" id="footnote-18">Cinosi E, Martinotti G, Simonato P, et al. <a href="https://doi.org/10.1155/2015/968786">Following "the roots" of kratom (<em>Mitragyna speciosa</em>): The evolution of an enhancer from a traditional use to increase work and productivity in southeast Asia to a recreational psychoactive drug in western countries</a>. <em>Biomed Res Int</em>. 2015;2015:968786. doi:10.1155/2015/968786 <a href="#reference-18">[18]</a></li><li class="long-url-wrap" id="footnote-19">Henningfield JE, Grundmann O, Garcia-Romeu A, Swogger MT. <a href="https://doi.org/10.1016/j.amepre.2021.07.022">We need better estimates of kratom use prevalence.</a> <em>Am J Prev Med</em>. 2022;62(1):132-133. doi:10.1016/j.amepre.2021.07.022 <a href="#reference-19">[19]</a></li><li class="long-url-wrap" id="footnote-20">Prozialeck WC, Jivan JK, Andurkar SV. <a href="https://pubmed.ncbi.nlm.nih.gov/23212430/">Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.</a> <em>J Am Osteopath Assoc</em>. 2012;112(12):792-799. <a href="#reference-20">[20]</a></li><li class="long-url-wrap" id="footnote-21">Dixon RB, Waggoner D, Davis M, Rembold K, Dasgupta A. <a href="https://pubmed.ncbi.nlm.nih.gov/31611214/">Contamination of some kratom products with <em>Salmonella</em>.</a><em> Ann Clin Lab Sci</em>. 2019;49(5):675-677. <a href="#reference-21">[21]</a></li><li class="long-url-wrap" id="footnote-22">Eastlack SC, Cornett EM, Kaye AD. <a href="https://doi.org/10.1007/s40122-020-00151-x">Kratom-pharmacology, clinical implications, and outlook: A comprehensive review.</a> <em>Pain Ther</em>. 2020;9(1):55-69. doi:10.1007/s40122-020-00151-x <a href="#reference-22">[22]</a></li><li class="long-url-wrap" id="footnote-23">Graves JM, Dilley JA, Terpak L, et al. <a href="https://doi.org/10.1111/jgs.17326">Kratom exposures among older adults reported to U.S. poison centers, 2014-2019.</a> <em>J Am Geriatr Soc</em>. 2021;69(8):2176-2184. doi:10.1111/jgs.17326 <a href="#reference-23">[23]</a></li><li class="long-url-wrap" id="footnote-24">Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. <a href="https://doi.org/10.1002/phar.2280">Kratom use and toxicities in the United States.</a> <em>Pharmacotherapy</em>. 2019;39(7):775-777. doi:10.1002/phar.2280 <a href="#reference-24">[24]</a></li><li class="long-url-wrap" id="footnote-25">Veltri C, Grundmann O. <a href="https://doi.org/10.2147/sar.s164261">Current perspectives on the impact of Kratom use.</a> <em>Subst Abuse Rehabil.</em> 2019;10:23-31. Published 2019 Jul 1. doi:10.2147/SAR.S164261 <a href="#reference-25">[25]</a></li><li class="long-url-wrap" id="footnote-26">Schimmel J, Dart RC. <a href="https://doi.org/10.1007/s40265-019-01242-6">Kratom (<em>Mitragyna speciosa</em>) liver injury: A comprehensive review.</a> <em>Drugs</em>. 2020;80(3):263-283. doi:10.1007/s40265-019-01242-6 <a href="#reference-26">[26]</a></li><li class="long-url-wrap" id="footnote-27">Kruegel AC, Uprety R, Grinnell SG, et al. <a href="https://doi.org/10.1021/acscentsci.9b00141">7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects.</a> <em>ACS Cent Sci</em>. 2019;5(6):992-1001. doi:10.1021/acscentsci.9b00141 <a href="#reference-27">[27]</a></li><li class="long-url-wrap" id="footnote-28">Kruegel AC, Gassaway MM, Kapoor A, et al. <a href="https://doi.org/10.1021/jacs.6b00360">Synthetic and receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators.</a> <em>J Am Chem Soc</em>. 2016;138(21):6754-6764. doi:10.1021/jacs.6b00360 <a href="#reference-28">[28]</a></li><li class="long-url-wrap" id="footnote-29">Váradi A, Marrone GF, Palmer TC, et al. <a href="https://doi.org/10.1021/acs.jmedchem.6b00748">Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2.</a> <em>J Med Chem</em>. 2016;59(18):8381-8397. doi:10.1021/acs.jmedchem.6b00748 <a href="#reference-29">[29]</a></li><li class="long-url-wrap" id="footnote-30">Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, et al. <a href="https://doi.org/10.1016/s0014-2999(96)00714-5">Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems.</a> Eur J Pharmacol. 1996;317(1):75–81. <a href="#reference-30">[30]</a></li><li class="long-url-wrap" id="footnote-31">Hanapi NA, Chear NJ, Azizi J, Yusof SR. <a href="https://doi.org/10.3389/fphar.2021.751656">Kratom alkaloids: Interactions with enzymes, receptors, and cellular barriers.</a> <em>Front Pharmacol</em>. 2021;12:751656. Published 2021 Nov 17. doi:10.3389/fphar.2021.751656 <a href="#reference-31">[31]</a></li><li class="long-url-wrap" id="footnote-32">Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. <a href="https://doi.org/10.1016/j.drugalcdep.2019.05.005">Kratom as a substitute for opioids: Results from an online survey.</a> <em>Drug Alcohol Depend</em>. 2019;202:24-32. doi:10.1016/j.drugalcdep.2019.05.005 <a href="#reference-32">[32]</a></li><li class="long-url-wrap" id="footnote-33">Charen E, Harbord N. <a href="https://doi.org/10.1053/j.ackd.2019.08.003">Toxicity of herbs, vitamins, and supplements.</a> <em>Adv Chronic Kidney Dis</em>. 2020;27(1):67-71. doi:10.1053/j.ackd.2019.08.003 <a href="#reference-33">[33]</a></li><li class="long-url-wrap" id="footnote-34">Hudson A, Lopez E, Almalki AJ, Roe AL, Calderón AI. <a href="https://doi.org/10.1055/a-0605-3786">A review of the toxicity of compounds found in herbal dietary supplements.</a> <em>Planta Med</em>. 2018;84(9-10):613-626. doi:10.1055/a-0605-3786 <a href="#reference-34">[34]</a></li><li class="long-url-wrap" id="footnote-35">Lu J, Wei H, Wu J, et al. <a href="https://doi.org/10.1371/journal.pone.0115648">Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.</a> <em>PLoS One</em>. 2014;9(12):e115648. Published 2014 Dec 23. doi:10.1371/journal.pone.0115648 <a href="#reference-35">[35]</a></li><li class="long-url-wrap" id="footnote-36">CDC WONDER. Multiple Cause of Death 1999-2020. Centers for Disease Control and Prevention, National Center on Health Statistics. Released December 2021. Accessed January 2022. <a href="#reference-36">[36]</a></li><li class="long-url-wrap" id="footnote-37">Wright ME, Ginsberg C, Parkison AM, Dubose M, Sherbondy M, Shores E. <a href="https://doi.org/10.1038/s41372-021-00952-8">Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review.</a> <em>J Perinatol</em>. 2021;41(6):1236-1243. doi:10.1038/s41372-021-00952-8 <a href="#reference-37">[37]</a></li><li class="long-url-wrap" id="footnote-38">Papsun DM, Chan-Hosokawa A, Friederich L, Brower J, Graf K, Logan B. <a href="https://doi.org/10.1093/jat/bkz064">The trouble with kratom: Analytical and interpretative issues involving mitragynine.</a> <em>J Anal Toxicol</em>. 2019;43(8):615-629. doi:10.1093/jat/bkz064 <a href="#reference-38">[38]</a></li><li class="long-url-wrap" id="footnote-39">Veltri C, Grundmann O. <a href="https://doi.org/10.1093/jat/bkz012">Association of kratom use with impairment: Many legal questions remain.</a> <em>J Anal Toxicol</em>. 2019;43(5):e8-e9. doi:10.1093/jat/bkz012 <a href="#reference-39">[39]</a></li><li class="long-url-wrap" id="footnote-40">American Psychiatric Association. <a href="https://www.psychiatry.org/file%20library/psychiatrists/practice/dsm/apa_dsm-5-substance-use-disorder.pdf">Substance-related and addictive disorders</a>. <em>Diagnostic and Statistical Manual of Mental Disorders.</em> 5th ed. Washington D.C.: 2013. doi:10.1176/appi.books.9780890425596.dsm16 <a href="#reference-40">[40]</a></li><li class="long-url-wrap" id="footnote-41">Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. <a href="https://doi.org/10.1080/02791072.2018.1562133">Kratom withdrawal: A systematic review with case series.</a> <em>J Psychoactive Drugs</em>. 2019;51(1):12-18. doi:10.1080/02791072.2018.1562133 <a href="#reference-41">[41]</a></li><li class="long-url-wrap" id="footnote-42">Singh D, Narayanan S, Vicknasingam BK, et al. <a href="https://doi.org/10.1080/02791072.2018.1443234">Severity of pain and sleep problems during kratom (<em>Mitragyna speciosa </em>korth) cessation among regular kratom users.</a> <em>J Psychoactive Drugs</em>. 2018;50(3):266-274. doi:10.1080/02791072.2018.1443234 <a href="#reference-42">[42]</a></li><li class="long-url-wrap" id="footnote-43">Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. <a href="https://pubmed.ncbi.nlm.nih.gov/29949228/">Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.</a> <em>Addict Biol</em>. 2019;24(5):874-885. doi:10.1111/adb.12639 <a href="#reference-43">[43]</a></li><li class="long-url-wrap" id="footnote-44">Khazaeli A, Jerry JM, Vazirian M. <a href="https://doi.org/10.1097/adm.0000000000000721">Treatment of kratom withdrawal and addiction With buprenorphine.</a> <em>J Addict Med</em>. 2018;12(6):493-495. doi:10.1097/ADM.0000000000000435 <a href="#reference-44">[44]</a></li><li class="long-url-wrap" id="footnote-45">Vento AE, de Persis S, De Filippis S, et al. <a href="https://doi.org/10.3389/fpsyt.2021.640218">Case report: Treatment of kratom use disorder with a classical tricyclic antidepressant.</a> <em>Front Psychiatry</em>. 2021;12:640218. Published 2021 Mar 31. doi:10.3389/fpsyt.2021.640218 <a href="#reference-45">[45]</a></li><li class="long-url-wrap" id="footnote-46">Hassan R, Sreenivasan S, Müller CP, Hassan Z. <a href="https://doi.org/10.3389/fphar.2021.708019">Methadone, buprenorphine, and clonidine attenuate mitragynine withdrawal in rats.</a> <em>Front Pharmacol</em>. 2021;12:708019. Published 2021 Jul 12. doi:10.3389/fphar.2021.708019 <a href="#reference-46">[46]</a></li><li class="long-url-wrap" id="footnote-47">Kalin S, Dakhlalla S, Bhardwaj S. <a href="https://doi.org/10.5055/jom.2020.0594">Treatment for kratom abuse in a contingency-management-based MAT setting: A case series.</a> <em>J Opioid Manag</em>. 2020;16(5):391-394. doi:10.5055/jom.2020.0594 <a href="#reference-47">[47]</a></li><li class="long-url-wrap" id="footnote-48">Grundmann O, Brown PN, Henningfield J, Swogger M, Walsh Z. <a href="https://doi.org/10.1111/add.14371">The therapeutic potential of kratom.</a> <em>Addiction</em>. 2018;113(10):1951-1953. doi:10.1111/add.14371 <a href="#reference-48">[48]</a></li><li class="long-url-wrap" id="footnote-49">Williams RS, Nikitin D. <a href="https://doi.org/10.1016/j.drugpo.2020.102715">The internet market for kratom, an opioid alternative and variably legal recreational drug.</a> <em>Int J Drug Policy</em>. 2020;78:102715. doi:10.1016/j.drugpo.2020.102715 <a href="#reference-49">[49]</a></li></ol></div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</article>
|
||
|
||
<aside class="layout-sidebar-right article-aside" role="complementary">
|
||
<div class="citation-block" id="block-citation">
|
||
|
||
|
||
<div class="citation">
|
||
<button class="citation-header button button-primary-alt button--small" aria-expanded="false" tabindex="0">
|
||
<span class="pointer-background"><i class="fas fa-quote-left"></i> Cite this article</span>
|
||
</button>
|
||
<div class="citation-content">
|
||
<div class="tabs-wrapper">
|
||
<button class="tab-button active button button-secondary-alt button--small" data-click="selectme1">APA Style</button>
|
||
<button class="tab-button button button-secondary-alt button--small" data-click="selectme2">MLA Style</button>
|
||
<button class="tab-button button button-secondary-alt button--small" data-click="selectme3">AMA Style</button>
|
||
</div>
|
||
|
||
<div id="selectme1" class="selectme">
|
||
<p>
|
||
NIDA. 2022, March 25. Kratom. Retrieved from https://nida.nih.gov/research-topics/kratom on 2025, March 16 </p>
|
||
</div>
|
||
|
||
<div id="selectme2" class="selectme" style="display:none;">
|
||
<p>
|
||
NIDA. "Kratom." <em>National Institute on Drug Abuse</em>, 25 Mar. 2022, https://nida.nih.gov/research-topics/kratom Accessed 16 Mar. 2025. </p>
|
||
</div>
|
||
|
||
<div id="selectme3" class="selectme" style="display:none;">
|
||
<p>
|
||
NIDA. Kratom. National Institute on Drug Abuse website. https://nida.nih.gov/research-topics/kratom. March 25, 2022 Accessed March 16, 2025. </p>
|
||
</div>
|
||
<div class="copy-message">
|
||
<span class="smaller">press ctrl+c to copy</span>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div id="block-addtoanybuttons" class="mt-0-5">
|
||
<span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="https://nida.nih.gov/research-topics/kratom" data-a2a-title="Kratom"><p class="sidebar-heading a2a-buttons--heading">Share this Page</p><div class="a2a-buttons--flex"><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_x"></a><a class="a2a_button_linkedin"></a><a class="a2a_button_print"></a></div></span>
|
||
|
||
</div>
|
||
<div class="emergency-block--wrapper">
|
||
<div id="block-inanemergencyredbox">
|
||
|
||
|
||
|
||
<div><div class="emergency-box l-padding" style="font-size:90%!important;">
|
||
<h2 class="h3">In an emergency? Need treatment?</h2>
|
||
<div class="expand-button expand-button--plus expand-button--icon-before font-primary js-expandmore">Expand for more information</div>
|
||
<div id="emergency-resources" class="js-to_expand long-url-wrap">
|
||
<h3>IN AN EMERGENCY:</h3>
|
||
<ul style="margin-left:1.3rem;">
|
||
<li><strong>Are you or someone you know experiencing severe symptoms or in immediate danger?</strong>
|
||
Please seek immediate medical attention by <strong>calling 9-1-1</strong> or <strong>visiting an Emergency Department</strong>. Poison control can be reached at <a href="tel:1-800-222-1222" style="color:#A42629; border-color:#A42629;">1-800-222-1222</a> or <a href="https://www.poison.org" style="color:#A42629; border-color:#A42629;">www.poison.org</a>.
|
||
</li>
|
||
|
||
<li><strong>Are you or someone you know experiencing a substance use and/or mental health crisis or any other kind of emotional distress?</strong> Please <strong>call or text 988</strong> or chat <a href="https://www.988lifeline.org" style="color:#A42629; border-color:#A42629;">www.988lifeline.org</a> to reach the 988 Suicide & Crisis Lifeline. 988 connects you with a trained crisis counselor who can help.</li>
|
||
</ul>
|
||
|
||
<h3>FIND TREATMENT:</h3>
|
||
<ul style="margin-left:1.3rem;">
|
||
<li>For referrals to substance use and mental health treatment programs, call the Substance Abuse and Mental Health Administration (SAMHSA) National Helpline at <a href="tel:1-800-6620-4357" style="color:#A42629; border-color:#A42629;">1-800-662-HELP (4357)</a> or visit <a href="https:///www.findtreatment.gov" style="color:#A42629; border-color:#A42629;">www.FindTreatment.gov</a> to find a qualified healthcare provider in your area.</li>
|
||
<li>For other personal medical advice, please speak to a qualified health professional. Find more health resources on <a href="https://www.usa.gov/health" style="color:#A42629; border-color:#A42629;">USA.gov</a>.</li>
|
||
</ul>
|
||
|
||
<h3>DISCLAIMER:</h3>
|
||
|
||
<p><em>The emergency and referral resources listed above are available to individuals located in the United States and are not operated by the National Institute on Drug Abuse (NIDA). NIDA is a biomedical research organization and does not provide personalized medical advice, treatment, counseling, or legal consultation. Information provided by NIDA is not a substitute for professional medical care or legal consultation.</em></p>
|
||
</div>
|
||
</div></div>
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
</aside>
|
||
</div>
|
||
|
||
<div class="research-topic--bottom-matter">
|
||
</div>
|
||
</div>
|
||
|
||
<div class="article-meta pt-1-2">
|
||
|
||
<div class="meta-data text-small">
|
||
<span class="date">
|
||
<time datetime="2022-03-25T12:00:00Z">March 2022</time>
|
||
|
||
</span>
|
||
</div>
|
||
</div>
|
||
</article>
|
||
|
||
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
</main>
|
||
|
||
</div> </div>
|
||
|
||
<footer role="contentinfo" class="footer l-section l-section--dark">
|
||
|
||
<div class="l-inner row no-margin">
|
||
<nav role="navigation" aria-labelledby="block-solstice-footer-menu" id="block-solstice-footer" class="col-12 col-desktop-6">
|
||
|
||
<div class="visually-hidden" id="block-solstice-footer-menu">Footer menu</div>
|
||
|
||
|
||
|
||
<ul class="footer-links">
|
||
<li>
|
||
<a href="/" class="link" data-drupal-link-system-path="<front>">NIDA Home</a>
|
||
</li>
|
||
<li>
|
||
<a href="/research-topics" class="link" data-drupal-link-system-path="node/1861">Research Topics</a>
|
||
</li>
|
||
<li>
|
||
<a href="/research" class="link" data-drupal-link-system-path="node/22803">Research & Training</a>
|
||
</li>
|
||
<li>
|
||
<a href="/nidamed-medical-health-professionals" class="link" data-drupal-link-system-path="node/22863">NIDAMED: Clinical Resources</a>
|
||
</li>
|
||
<li>
|
||
<a href="/funding" class="link" data-drupal-link-system-path="node/22854">Grants & Funding</a>
|
||
</li>
|
||
<li>
|
||
<a href="/news-events" class="link" data-drupal-link-system-path="node/1860">News</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about-nida" class="link" data-drupal-link-system-path="node/2389">About NIDA</a>
|
||
</li>
|
||
<li>
|
||
<a href="https://public.govdelivery.com/accounts/USNIHNIDA/subscriber/new?qsp=USNIHNIDA_3" title="Subscribe" class="link">Subscribe to NIDA e-mail updates</a>
|
||
</li>
|
||
<li>
|
||
<a href="/accessibility-section-508-information" class="link" data-drupal-link-system-path="node/2753">Accessibility and Section 508 Information</a>
|
||
</li>
|
||
<li>
|
||
<a href="/privacy-notice" title="Privacy Notice" class="link" data-drupal-link-system-path="node/2754">Privacy Notice</a>
|
||
</li>
|
||
<li>
|
||
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="link">Vulnerability Disclosure (HHS)</a>
|
||
</li>
|
||
<li>
|
||
<a href="/freedom-information-act-foia" title="Freedom of Information Act (FOIA)" class="link" data-drupal-link-system-path="node/22972">Freedom of Information Act (FOIA)</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about-nida/working-nida" title="Working at NIDA" class="link" data-drupal-link-system-path="node/36660">Working at NIDA</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about-nida/frequently-asked-questions" title="Frequently Asked Questions" class="link" data-drupal-link-system-path="node/2777">Frequently Asked Questions</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about-nida/contact-us" title="Contact Us" class="link" data-drupal-link-system-path="node/378">Contact Us</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about-nida/sitemap" class="link" data-drupal-link-system-path="node/48387">Sitemap</a>
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</nav>
|
||
<div class="col-12 col-desktop-3 footer__subscribe">
|
||
<h3 class="text-accent">Sign Up for Our Newsletter</h3>
|
||
<form id="GD-snippet-form" action=https://public.govdelivery.com/accounts/USNIHNIDA/subscribers/qualify accept-charset="UTF-8" method="post"><input name="utf8" type="hidden" value="✓" />
|
||
<input type="hidden" name="topic_id" id="topic_id" value="USNIHNIDA_2" />
|
||
<p class="">Enter your email address</p>
|
||
<ol class='form'>
|
||
<li class='email_fields' style='display: block'>
|
||
<label for="email" class="visually-hidden">Email Address</label>
|
||
<input type="email" name="email" id="email" value="" class="long email_text_field email" required="required" placeholder="email address" style="1px solid #999; font-size:15px; margin-bottom:1rem; line-height:1.5; padding:.5rem .5rem;max-width:280px;" />
|
||
</li>
|
||
</ol>
|
||
<div class='button_panel'>
|
||
<input type="submit" name="commit" value="Subscribe" class="sr-button button button--small button button-primary-alt" data-disable-with="Submit" style="line-height:1.5;" />
|
||
</div>
|
||
</form>
|
||
<!-- /Gov delivery signup, NEW -->
|
||
</div>
|
||
<div id="block-othernidasites" class="col-12 col-desktop-3">
|
||
<div class="other-footer-links">
|
||
|
||
|
||
|
||
<div><h3 class="text-accent">Other NIDA Sites</h3>
|
||
|
||
<ul class="footer-links">
|
||
<li><a href="https://researchstudies.nida.nih.gov/">NIDA Research Studies in Baltimore</a></li>
|
||
<li><a href="https://irp.nida.nih.gov/">Intramural Research Program</a></li>
|
||
<li><a href="https://insite.nida.nih.gov/">Employee Intranet - Staff Only, Requires VPN</a></li>
|
||
</ul>
|
||
<h4 class="text-accent mb-0">Follow Us</h4>
|
||
<div class="social-media-white row space-between">
|
||
<a href="https://public.govdelivery.com/accounts/USNIHNIDA/subscriber/new?qsp=USNIHNIDA_3" class="social-media-email" aria-label="Contact NIDA"><i class="far fa-envelope" title="Envelope" role="img" aria-hidden="true"></i></a>
|
||
<a href="https://twitter.com/NIDAnews" class="social-media-twitter" aria-label="Follow us on Twitter"><i class="fab fa-x-twitter" title="Twitter" role="img" aria-hidden="true"></i></a>
|
||
<a href="https://www.facebook.com/NIDANIH" class="social-media-facebook" aria-label="Follow us on Facebook"><i class="fab fa-facebook-f" title="Facebook" role="img" aria-hidden="true"></i></a>
|
||
<a href="https://www.linkedin.com/company/the-national-institute-on-drug-abuse-nida" class="social-media-linkedin" aria-label="Follow us on LinkedIn"><i class="fab fa-linkedin-in" title="LinkedIn" role="img" aria-hidden="true"></i></a>
|
||
<a href="https://www.youtube.com/user/NIDANIH" class="social-media-youtube" aria-label="Follow us on YouTube"><i class="fab fa-youtube" title="YouTube" role="img" aria-hidden="true"></i></a>
|
||
<a href="https://www.flickr.com/photos/nida-nih/albums" class="social-media-flickr " aria-label="Follow us on Flickr"><i class="fab fa-flickr" title="Flickr" role="img" aria-hidden="true"></i></a>
|
||
</div></div>
|
||
|
||
</div>
|
||
</div>
|
||
<div id="block-footernihlinks" class="footer-links col-12 r-m-t-quad pt-1-2">
|
||
|
||
|
||
|
||
<div><ul class="nih-links"><li><a href="https://www.hhs.gov/">U.S. Department of Health and Human Services</a></li><li><a href="https://www.nih.gov/">National Institutes of Health</a></li><li><a href="/">National Institute on Drug Abuse</a></li><li><a href="https://usa.gov/">USA.gov</a></li></ul><p class="nih-links" style="color:white;">NIH...Turning Discovery Into Health ®</p></div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</footer>
|
||
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/48990","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"back_to_top":{"back_to_top_button_trigger":100,"back_to_top_speed":1200,"back_to_top_prevent_on_mobile":false,"back_to_top_prevent_in_admin":false,"back_to_top_button_type":"text","back_to_top_button_text":"Back to Top"},"clientside_validation_jquery":{"validate_all_ajax_forms":2,"force_validate_on_blur":false,"force_html5_validation":false,"messages":{"required":"This field is required.","remote":"Please fix this field.","email":"Please enter a valid email address.","url":"Please enter a valid URL.","date":"Please enter a valid date.","dateISO":"Please enter a valid date (ISO).","number":"Please enter a valid number.","digits":"Please enter only digits.","equalTo":"Please enter the same value again.","maxlength":"Please enter no more than {0} characters.","minlength":"Please enter at least {0} characters.","rangelength":"Please enter a value between {0} and {1} characters long.","range":"Please enter a value between {0} and {1}.","max":"Please enter a value less than or equal to {0}.","min":"Please enter a value greater than or equal to {0}.","step":"Please enter a multiple of {0}."}},"simple_survey":{"parentTag":"body","language":"en","attachStylesheet":true,"debug":false,"delay":35,"configDelay":7,"closingDelay":7,"displayDelayType":"time","configDelayPosition":"bottom","basePath":"\/simple-survey\/api\/nida_2023","questionsPath":"\/simple-survey\/api\/nida_2023\/survey-questions","submitPath":"\/simple-survey\/api\/nida_2023\/submit-questions","validationPath":null,"translations":false,"useFontAwesome":true,"ombDisclaimer":true,"ombId":"0925-0648","ombExpiration":"07-31-2027","ombLink":"https:\/\/nida.nih.gov\/privacy-notice#burden","startingQuestion":"22","survey":"nida_2023","displayCooldown":1,"answeredDisplayCooldown":1,"modulePath":"\/modules\/contrib\/simple_survey"},"data":{"extlink":{"extTarget":true,"extTargetAppendNewWindowLabel":"(opens in a new window)","extTargetNoOverride":false,"extNofollow":false,"extTitleNoOverride":false,"extNoreferrer":true,"extFollowNoOverride":false,"extClass":"ext","extLabel":"(link is external)","extImgClass":false,"extSubdomains":true,"extExclude":"(\\.gov)","extInclude":"","extCssExclude":".no-ext,\r\n.social-media","extCssInclude":"","extCssExplicit":"","extAlert":true,"extAlertText":"You are leaving the NIDA Website. This external link provides additional information that is consistent with the intended purpose of this federal site. The National Institute on Drug Abuse (NIDA) or the Department of Health and Human Services (HHS) cannot attest to the accuracy of a non-federal site. Linking to a non-federal site does not constitute an endorsement by NIDA, HHS, or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site\u2019s privacy policy when you follow the link.","extHideIcons":false,"mailtoClass":"mailto","telClass":"","mailtoLabel":"(link sends email)","telLabel":"(link is a phone number)","extUseFontAwesome":true,"extIconPlacement":"append","extPreventOrphan":false,"extFaLinkClasses":"fa-solid fa-arrow-up-right-from-square fa-xs","extFaMailtoClasses":"fa-solid fa-envelope-square","extAdditionalLinkClasses":"","extAdditionalMailtoClasses":"","extAdditionalTelClasses":"","extFaTelClasses":"fa fa-phone","whitelistedDomains":[],"extExcludeNoreferrer":""}},"ckeditorAccordion":{"accordionStyle":{"collapseAll":1,"keepRowsOpen":1,"animateAccordionOpenAndClose":1,"openTabsWithHash":1}},"field_group":{"html_element":{"mode":"default","context":"view","settings":{"classes":"section-header","id":"","element":"div","show_label":false,"label_element":"h3","label_element_classes":"","attributes":"","effect":"none","speed":"fast","show_empty_fields":false}}},"colorbox":{"transition":"elastic","speed":350,"opacity":0.85,"slideshow":false,"slideshowAuto":true,"slideshowSpeed":2500,"slideshowStart":"start slideshow","slideshowStop":"stop slideshow","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","overlayClose":true,"returnFocus":true,"maxWidth":"98%","maxHeight":"98%","initialWidth":"300","initialHeight":"250","fixed":true,"scrolling":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"mediaelement":{"attachSitewide":0},"user":{"uid":0,"permissionsHash":"c7edf0464a63651bd805b29836004762924e79bca07438bcc1190127674128c9"}}</script>
|
||
<script src="/sites/default/files/js/js_7OAqlj3QsrMlQOMyslTSjK1KTQ1YjIrhttP-dZSsGkU.js?scope=footer&delta=0&language=en&theme=solstice&include=eJxlj2sSgzAIhC8UzZEcTNCmwZAh2Ortm7a-Op3hx8fuAAt4rwxptbBBOwgnNT242CnXyvbC3b0YV31M2oFzLD5wsn-KKWHKhF2Z5YGr_elMYSoaHNqRuAdqiq4U0njqQ10HTyw8ocFFqxmtlzkDtVtrXEQflOUS4qDvB5i8cUFBPwE3aHpiF89LGQRGgXxrjun3f8TS82J3OBWPA8ykVRDcIw0s0wvDhIEB"></script>
|
||
<script src="https://static.addtoany.com/menu/page.js" defer></script>
|
||
<script src="/sites/default/files/js/js_Ym6WAkAsayaBpUPiQgeR4xjoepnsup504HlB6y9Gjhg.js?scope=footer&delta=2&language=en&theme=solstice&include=eJxlj2sSgzAIhC8UzZEcTNCmwZAh2Ortm7a-Op3hx8fuAAt4rwxptbBBOwgnNT242CnXyvbC3b0YV31M2oFzLD5wsn-KKWHKhF2Z5YGr_elMYSoaHNqRuAdqiq4U0njqQ10HTyw8ocFFqxmtlzkDtVtrXEQflOUS4qDvB5i8cUFBPwE3aHpiF89LGQRGgXxrjun3f8TS82J3OBWPA8ykVRDcIw0s0wvDhIEB"></script>
|
||
<script src="/modules/contrib/ckeditor_accordion/js/accordion.frontend.min.js?st4lha"></script>
|
||
<script src="/sites/default/files/js/js_fKNo1puIuiGaUSlq5O7WLkYsPigMURPT9oSl3MI6uB8.js?scope=footer&delta=4&language=en&theme=solstice&include=eJxlj2sSgzAIhC8UzZEcTNCmwZAh2Ortm7a-Op3hx8fuAAt4rwxptbBBOwgnNT242CnXyvbC3b0YV31M2oFzLD5wsn-KKWHKhF2Z5YGr_elMYSoaHNqRuAdqiq4U0njqQ10HTyw8ocFFqxmtlzkDtVtrXEQflOUS4qDvB5i8cUFBPwE3aHpiF89LGQRGgXxrjun3f8TS82J3OBWPA8ykVRDcIw0s0wvDhIEB"></script>
|
||
|
||
</body>
|
||
</html>
|